Publication

Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer

Grewal, A. S., Schonewolf, C., Min, E. J., Chao, H-H., Both, S., Lam, S., Mazzoni, S., Bekelman, J., Christodouleas, J. & Vapiwala, N., 15-Nov-2019, In : International Journal of Radiation Oncology Biology Physics. 105, 4, p. 713-722 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer

    Final publisher's version, 655 KB, PDF document

    Request copy

DOI

  • Amardeep S. Grewal
  • Caitlin Schonewolf
  • Eun Jeong Min
  • Hann-Hsiang Chao
  • Stefan Both
  • Sarah Lam
  • Susan Mazzoni
  • Justin Bekelman
  • John Christodouleas
  • Neha Vapiwala

Purpose: Moderately hypofractionated radiation therapy represents an effective treatment for localized prostate cancer (PC). Although large randomized trials have reported the efficacy of photon-based hypofractionated therapy, hypofractionated proton therapy (HFPT) has not been extensively studied. This study was performed to determine the clinical and patient-reported outcomes for patients with PC treated with HFPT.

Methods and Materials: Between 2010 and 2017, 184 men were enrolled on a trial of 70 Gy in 28 fractions of HFPT for low- to intermediate-risk PC. Acute and late toxicity was evaluated using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Patient-reported outcomes were measured by International Prostate Symptom Score, International Index of Erectile Function Questionnaire, and Expanded Prostate Cancer Index Composite scores.

Results: Median follow-up was 49.2 months. Enrolled patients had low-risk (n = 18), favorable intermediate-risk (n = 78), and unfavorable intermediate-risk (n = 88) PC. Four-year rates of biochemical-clinical failure-free survival were 93.5% (95% confidence interval, 89%-98%), 94.4% (89%-100%), 92.5% (86%-100%), and 93.8% (88%-100%) in the overall group and the low-risk, favorable intermediate-risk, and unfavorable intermediate-risk cohorts, respectively (log-rank P > .4). The incidence of acute grade 2 or higher gastrointestinal (GI) and urologic toxicities were 3.8% and 12.5%, respectively. The 4-year incidence of late grade 2 or higher urologic and GI toxicity was 7.6% (4%-13%) and 13.6% (9%-20%), respectively. One late grade 3 GI toxicity was reported. All late toxicities were transient. Patient-reported International Prostate Symptom, International Index of Erectile Function, and Expanded Prostate Cancer Index Composite scores had no significant long-term changes after completion of HFPT (Supplementary Table 1, available at https://doi.org/10.1016/j.ijrobp.2019.05.069).

Conclusions: HFPT is associated with low rates of toxicity and does not appear to negatively affect 4-year patient reported urinary and bowel health. Further comparative analyses are warranted to better understand differences between proton and photon HFRT. (C) 2019 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)713-722
Number of pages10
JournalInternational Journal of Radiation Oncology Biology Physics
Volume105
Issue number4
Publication statusPublished - 15-Nov-2019

    Keywords

  • INTENSITY-MODULATED RADIOTHERAPY, PATIENT-REPORTED OUTCOMES, RADIATION-THERAPY, SERUM TESTOSTERONE, BEAM RADIOTHERAPY, RANDOMIZED-TRIAL, 5-YEAR OUTCOMES, TOXICITY, FRACTIONATION, ASSOCIATION

View graph of relations

ID: 102269031